Showing results (1-10 of 235) with videos related to
Sort By:
Pageof 24
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 22, 2009
[Rituximab resistance in B-cell lymphoma and its elimination]Kiyohiko Hatake, Yasuhito TeruiNihon Rinsho. Japanese Journal of Clinical Medicine|July 31, 2004
[Rituximab and hematological malignancy]Kiyohiko Hatake, Yuko Mishima, Yasuhito TeruiGan to Kagaku Ryoho. Cancer & Chemotherapy|July 27, 2004
[Proteasome inhibitors]Kiyohiko Hatake, Yuko Mishima, Yasuhito TeruiGan to Kagaku Ryoho. Cancer & Chemotherapy|August 10, 2007
[Recent progress in rituximab therapy and its resistance--how do we overcome?]Kiyohiko Hatake, Masahiro Yokoyama, Yasuhito Terui[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|September 9, 2017
Combination therapy with monoclonal antibodies for treatment of newly diagnosed multiple myelomaNoriko Nishimura, Yasuhito Terui, Kiyohiko HatakeCancer|August 23, 2011
Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumabSatoshi Matsusaka, Yuji Mishima, Mitsukuni Suenaga, et al.Cancer Chemotherapy and Pharmacology|December 21, 2010
Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancerSatoshi Matsusaka, Mitsukuni Suenaga, Yuji Mishima, et al.Cancer Science|February 3, 2007
Continuous treatment of bestatin induces anti-angiogenic property in endothelial cellsYuji Mishima, Yasuhito Terui, Natsuhiko Sugimura, et al.Cancer Science|March 16, 2011
Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancerSatoshi Matsusaka, Mitsukuni Suenaga, Yuji Mishima, et al.Leukemia & Lymphoma|December 11, 2012
Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapyKyoko Ueda, Yasuhito Terui, Masahiro Yokoyama, et al.Pageof 24